SK Group bets on biotechnology as energy business slows
Korean conglomerate SK Group plans to spend $1 billion to build a biotechnology business, which it hopes will offset slow growth in its existing businesses.
SK Group, Korea's fourth-largest conglomerate, plans to spend $1 billion to build a biotechnology business, whose profits it hopes will offset slowing growth in its energy and chemicals arms. The Seoul-based company says it wants to make "life sciences", which refers to pharmaceuticals, agricultural and industrial products developed using living organisms and genetic technology, the third pillar of its business, alongside telecommunications and energy.SK Group is starting more or less…
Sign In to Your Account
Access Exclusive AsianInvestor Content!
Please sign in to your subscription to unlock full access to our premium AI resources.
Free Registration & 7-Day Trial
Register now to enjoy a 7-day free trial—no registration fees required. Click the link to get started.
Note: This free trial is a one-time offer.